Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Case series:No
Control group:No
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Exposure group: HIV-infected subjects who received the new crown vaccine: (1) HIV antibody positive by Western blotting and a report of HIV diagnosis; (2) Aged 18 to 65 years; (3) Received two doses of Kexings new crown vaccine recently, and the interval between two doses of vaccine is 3-5 weeks; (4) Within 2-4 weeks of receiving the second dose of Kexings new crown vaccine; (5) Signed a written informed consent for the investigation content and laboratory testing items of this project, and are willing to participate in a 6-month follow-up investigation. 2. Control group: Non-HIV-infected subjects who received the new crown vaccine: (1) Those who are negative for HIV antibodies in the on-site blood HIV rapid test; (2) Aged 18 to 65 years; (3) Received two doses of Kexings new crown vaccine recently, and the interval between two doses of vaccine is 3-5 weeks; (4) Within 2-4 weeks of receiving the second dose of Kexings new crown vaccine; (5) Signed written informed consent for the investigation content and laboratory testing items of this project, and are willing to participate in the 6-month follow-up investigation; (6) Those who match the characteristics (age, gender, ethnicity, and length of time after vaccination) of HIV-infected persons enrolled in this project.
Exclusion criteria
Exclusion criteria: 1. Exposure group: HIV-infected subjects who received the new crown vaccine: (1) Patients with serious mental and neurological diseases; (2) Those with intellectual disabilities or those who cannot communicate effectively with researchers. 2. Control group: Non-HIV-infected subjects who received the new crown vaccine: (1) Patients with serious mental and neurological diseases; (2) Those with intellectual disabilities or those who cannot communicate effectively with researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Adverse Effect;total antibody;neutralizing antibody; | — |
Countries
China
Contacts
Public ContactXu Junjie
Peking University Shenzhen Hospital
Outcome results
None listed